OR WAIT null SECS
November 17, 2026
Video
Watch the top HCPLive video interviews from 2026 dermatology meetings, including AAD, RAD, EADV, Maui Derm, SDPA, and Fall Clinical.
October 15, 2026
Article
A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.
October 13, 2026
David Rosmarin, MD, discusses 52-week phase 2b REZOLVE-AA data on rezpegaldesleukin in severe alopecia areata presented at EADV 2026.
October 02, 2026
From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.
September 25, 2026
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
August 25, 2026
In this segment of his Q&A interview, Charles Lynde, MD, reviews upadacitinib's safety profile in the UP-AA trials and how it could reshape alopecia areata care.
August 24, 2026
In this Q&A, Charles Lynde, MD, highlighted upadacitinib's impact on severe alopecia areata in new phase 3 data addressing the hair loss condition.
August 21, 2026
This Q&A interview continues Gooderham's discussion of new upadacitinib treatment data on patients living with severe alopecia areata.
August 20, 2026
This Q&A interview highlights key new data from the UP-AA1 and UP-AA2 trials on upadacitinib for severe alopecia areata.
In this interview, Melinda Gooderham, MD, MSc, touches on eyebrow and eyelash regrowth data and safety findings for upadacitinib in severe alopecia areata.